Clinical validation of an in-house quantitative real time PCR assay for cytomegalovirus infection using the 1st WHO International Standard in kidney transplant patients

Abstract Introduction: Cytomegalovirus (CMV) is one of the most common agents of infection in solid organ transplant patients, with significant morbidity and mortality. Objective: This study aimed to establish a threshold for initiation of preemptive treatment. In addition, the study compared the performance of antigenemia with qPCR results. Study design: This was a prospective cohort study conducted in 2017 in a single kidney transplant center in Brazil. Clinical validation was performed by comparing in-house qPCR results, against standard of care at that time (Pp65 CMV Antigenemia). ROC curve analysis was performed to determine the ideal threshold for initiation of preemptive therapy based on the qPCR test results. Results: Two hundred and thirty two samples from 30 patients were tested with both antigenemia and qPCR, from which 163 (70.26%) were concordant (Kappa coefficient: 0.435, p<0.001; Spearman correlation: 0.663). PCR allowed for early diagnoses. The median number of days for the first positive result was 50 (range, 24-105) for antigenemia and 42 (range, 24-74) for qPCR (p<0.001). ROC curve analysis revealed that at a threshold of 3,430 IU/mL (Log 3.54), qPCR had a sensitivity of 97.06% and a specificity of 74.24% (AUC 0.92617 ± 0.0185, p<0.001), in the prediction of 10 cells/105 leukocytes by antigenemia and physician's decision to treat. Conclusions: CMV Pp65 antigenemia and CMV qPCR showed fair agreement and a moderate correlation in this study. The in-house qPCR was revealed to be an accurate method to determine CMV DNAemia in kidney transplant patients, resulting in positive results weeks before antigenemia.

Saved in:
Bibliographic Details
Main Authors: Caurio,Cassia F.B., Allende,Odelta S., Kist,Roger, Santos,Kênya L., Vasconcellos,Izadora C.S., Rozales,Franciéli P., Lana,Daiane F. Dalla, Praetzel,Bruno M., Alegretti,Ana Paula, Pasqualotto,Alessandro C.
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Nefrologia 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000400530
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0101-28002021000400530
record_format ojs
spelling oai:scielo:S0101-280020210004005302021-12-06Clinical validation of an in-house quantitative real time PCR assay for cytomegalovirus infection using the 1st WHO International Standard in kidney transplant patientsCaurio,Cassia F.B.Allende,Odelta S.Kist,RogerSantos,Kênya L.Vasconcellos,Izadora C.S.Rozales,Franciéli P.Lana,Daiane F. DallaPraetzel,Bruno M.Alegretti,Ana PaulaPasqualotto,Alessandro C. Cytomegalovirus PCR Drug Therapy Diagnosis Abstract Introduction: Cytomegalovirus (CMV) is one of the most common agents of infection in solid organ transplant patients, with significant morbidity and mortality. Objective: This study aimed to establish a threshold for initiation of preemptive treatment. In addition, the study compared the performance of antigenemia with qPCR results. Study design: This was a prospective cohort study conducted in 2017 in a single kidney transplant center in Brazil. Clinical validation was performed by comparing in-house qPCR results, against standard of care at that time (Pp65 CMV Antigenemia). ROC curve analysis was performed to determine the ideal threshold for initiation of preemptive therapy based on the qPCR test results. Results: Two hundred and thirty two samples from 30 patients were tested with both antigenemia and qPCR, from which 163 (70.26%) were concordant (Kappa coefficient: 0.435, p<0.001; Spearman correlation: 0.663). PCR allowed for early diagnoses. The median number of days for the first positive result was 50 (range, 24-105) for antigenemia and 42 (range, 24-74) for qPCR (p<0.001). ROC curve analysis revealed that at a threshold of 3,430 IU/mL (Log 3.54), qPCR had a sensitivity of 97.06% and a specificity of 74.24% (AUC 0.92617 ± 0.0185, p<0.001), in the prediction of 10 cells/105 leukocytes by antigenemia and physician's decision to treat. Conclusions: CMV Pp65 antigenemia and CMV qPCR showed fair agreement and a moderate correlation in this study. The in-house qPCR was revealed to be an accurate method to determine CMV DNAemia in kidney transplant patients, resulting in positive results weeks before antigenemia.info:eu-repo/semantics/openAccessSociedade Brasileira de NefrologiaBrazilian Journal of Nephrology v.43 n.4 20212021-12-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000400530en10.1590/2175-8239-jbn-2020-0214
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Caurio,Cassia F.B.
Allende,Odelta S.
Kist,Roger
Santos,Kênya L.
Vasconcellos,Izadora C.S.
Rozales,Franciéli P.
Lana,Daiane F. Dalla
Praetzel,Bruno M.
Alegretti,Ana Paula
Pasqualotto,Alessandro C.
spellingShingle Caurio,Cassia F.B.
Allende,Odelta S.
Kist,Roger
Santos,Kênya L.
Vasconcellos,Izadora C.S.
Rozales,Franciéli P.
Lana,Daiane F. Dalla
Praetzel,Bruno M.
Alegretti,Ana Paula
Pasqualotto,Alessandro C.
Clinical validation of an in-house quantitative real time PCR assay for cytomegalovirus infection using the 1st WHO International Standard in kidney transplant patients
author_facet Caurio,Cassia F.B.
Allende,Odelta S.
Kist,Roger
Santos,Kênya L.
Vasconcellos,Izadora C.S.
Rozales,Franciéli P.
Lana,Daiane F. Dalla
Praetzel,Bruno M.
Alegretti,Ana Paula
Pasqualotto,Alessandro C.
author_sort Caurio,Cassia F.B.
title Clinical validation of an in-house quantitative real time PCR assay for cytomegalovirus infection using the 1st WHO International Standard in kidney transplant patients
title_short Clinical validation of an in-house quantitative real time PCR assay for cytomegalovirus infection using the 1st WHO International Standard in kidney transplant patients
title_full Clinical validation of an in-house quantitative real time PCR assay for cytomegalovirus infection using the 1st WHO International Standard in kidney transplant patients
title_fullStr Clinical validation of an in-house quantitative real time PCR assay for cytomegalovirus infection using the 1st WHO International Standard in kidney transplant patients
title_full_unstemmed Clinical validation of an in-house quantitative real time PCR assay for cytomegalovirus infection using the 1st WHO International Standard in kidney transplant patients
title_sort clinical validation of an in-house quantitative real time pcr assay for cytomegalovirus infection using the 1st who international standard in kidney transplant patients
description Abstract Introduction: Cytomegalovirus (CMV) is one of the most common agents of infection in solid organ transplant patients, with significant morbidity and mortality. Objective: This study aimed to establish a threshold for initiation of preemptive treatment. In addition, the study compared the performance of antigenemia with qPCR results. Study design: This was a prospective cohort study conducted in 2017 in a single kidney transplant center in Brazil. Clinical validation was performed by comparing in-house qPCR results, against standard of care at that time (Pp65 CMV Antigenemia). ROC curve analysis was performed to determine the ideal threshold for initiation of preemptive therapy based on the qPCR test results. Results: Two hundred and thirty two samples from 30 patients were tested with both antigenemia and qPCR, from which 163 (70.26%) were concordant (Kappa coefficient: 0.435, p<0.001; Spearman correlation: 0.663). PCR allowed for early diagnoses. The median number of days for the first positive result was 50 (range, 24-105) for antigenemia and 42 (range, 24-74) for qPCR (p<0.001). ROC curve analysis revealed that at a threshold of 3,430 IU/mL (Log 3.54), qPCR had a sensitivity of 97.06% and a specificity of 74.24% (AUC 0.92617 ± 0.0185, p<0.001), in the prediction of 10 cells/105 leukocytes by antigenemia and physician's decision to treat. Conclusions: CMV Pp65 antigenemia and CMV qPCR showed fair agreement and a moderate correlation in this study. The in-house qPCR was revealed to be an accurate method to determine CMV DNAemia in kidney transplant patients, resulting in positive results weeks before antigenemia.
publisher Sociedade Brasileira de Nefrologia
publishDate 2021
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002021000400530
work_keys_str_mv AT cauriocassiafb clinicalvalidationofaninhousequantitativerealtimepcrassayforcytomegalovirusinfectionusingthe1stwhointernationalstandardinkidneytransplantpatients
AT allendeodeltas clinicalvalidationofaninhousequantitativerealtimepcrassayforcytomegalovirusinfectionusingthe1stwhointernationalstandardinkidneytransplantpatients
AT kistroger clinicalvalidationofaninhousequantitativerealtimepcrassayforcytomegalovirusinfectionusingthe1stwhointernationalstandardinkidneytransplantpatients
AT santoskenyal clinicalvalidationofaninhousequantitativerealtimepcrassayforcytomegalovirusinfectionusingthe1stwhointernationalstandardinkidneytransplantpatients
AT vasconcellosizadoracs clinicalvalidationofaninhousequantitativerealtimepcrassayforcytomegalovirusinfectionusingthe1stwhointernationalstandardinkidneytransplantpatients
AT rozalesfrancielip clinicalvalidationofaninhousequantitativerealtimepcrassayforcytomegalovirusinfectionusingthe1stwhointernationalstandardinkidneytransplantpatients
AT lanadaianefdalla clinicalvalidationofaninhousequantitativerealtimepcrassayforcytomegalovirusinfectionusingthe1stwhointernationalstandardinkidneytransplantpatients
AT praetzelbrunom clinicalvalidationofaninhousequantitativerealtimepcrassayforcytomegalovirusinfectionusingthe1stwhointernationalstandardinkidneytransplantpatients
AT alegrettianapaula clinicalvalidationofaninhousequantitativerealtimepcrassayforcytomegalovirusinfectionusingthe1stwhointernationalstandardinkidneytransplantpatients
AT pasqualottoalessandroc clinicalvalidationofaninhousequantitativerealtimepcrassayforcytomegalovirusinfectionusingthe1stwhointernationalstandardinkidneytransplantpatients
_version_ 1756392740261724160